miR-144 attenuates the host response to influenza virus by targeting the TRAF6-IRF7 signaling axis

• Carrie M. Rosenberger ,

  * E-mail: rosenberger.carrie@gene.com (CMR); alan.aderem@cidresearch.org (AA)

  Current address: Genentech, Inc., South San Francisco, CA United States of America

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯
• Rebecca L. Podyminogin,

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯
• Alan H. Diercks,

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯
• Piper M. Treuting,

  Affiliation Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, WA, United States of America

  ⨯
• Jacques J. Peschon,

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯
• David Rodriguez,

  Current address: Novo Nordisk, Inc., Seattle, WA United States of America

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯
• Madhumati Gundapuneni,

  Affiliation Institute for Systems Biology, Seattle, WA, United States of America

  ⨯
• Mitchell J. Weiss,

  Affiliation Hematology, St. Jude Children's Research Hospital, Memphis, TN United States of America

  ⨯
• Alan Aderem

  * E-mail: rosenberger.carrie@gene.com (CMR); alan.aderem@cidresearch.org (AA)

  Affiliation Center for Infectious Disease Research, Seattle, WA United States of America

  ⨯